Aptevo Therapeutics (APVO) Cash from Investing Activities (2015 - 2022)
Aptevo Therapeutics (APVO) posted Cash from Investing Activities of -$4000.0 for Q3 2022, up 96.61% sequentially from -$118000.0 in Q4 2021, and up 69.23% YoY from -$2363.6 in Q3 2021.
Aptevo Therapeutics (APVO) Cash from Investing Activities (2015 - 2022) Analysis & Trends
Aptevo Therapeutics has reported Cash from Investing Activities for 8 years, with the latest figure at -$4000.0 in Q3 2022.
- Quarterly Cash from Investing Activities rose 69.23% year-over-year to -$4000.0 in Q3 2022, while the trailing twelve-month figure through Mar 2026 was -$4000.0 (up 96.72% YoY) and the FY2022 annual result came in at -$29000.0, up 95.93% from the prior year.
- Cash from Investing Activities improved to -$4000.0 in Q3 2022 per APVO's latest filing, from -$118000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $63.8 million in Q3 2018 and troughed at -$391000.0 in Q2 2021.
- A 5-year average of $12.9 million and a median of -$8500.0 in 2021 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2020 and 2021: Cash from Investing Activities jumped 18479.08% in 2020, then sank 100.68% in 2021.
- Over 5 years, Cash from Investing Activities stood at $63.8 million in 2018, then plunged by 93.33% to $4.2 million in 2019, then sank by 102.07% to -$88000.0 in 2020, then plunged by 34.09% to -$118000.0 in 2021, then soared by 96.61% to -$4000.0 in 2022.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$4000.0, -$118000.0, and -$13000.0 for Q3 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -4,000.00 |
| Sep 30, 2022 | -4,000.00 |
| Dec 31, 2021 | -118,000.00 |
| Dec 31, 2021 | -118,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Jun 30, 2021 | -391,000.00 |
| Jun 30, 2021 | -391,000.00 |
| Mar 31, 2021 | -191,000.00 |
| Mar 31, 2021 | -191,000.00 |
| Dec 31, 2020 | -88,000.00 |
| Dec 31, 2020 | -88,000.00 |
| Mar 31, 2020 | 28.12 Mn |
| Mar 31, 2020 | 28.12 Mn |
| Sep 30, 2019 | 4.25 Mn |
| Sep 30, 2019 | 4.25 Mn |
| Mar 31, 2019 | -153,000.00 |
| Mar 31, 2019 | -153,000.00 |
| Sep 30, 2018 | 63.76 Mn |
| Sep 30, 2018 | 63.76 Mn |